Completed PHASE3 INTERVENTIONAL 2-arm NCT02726269

Triple Therapy Versus Levofloxacin-based Therapy for Helicobacter Pylori Eradication in Mexico.

Helicobacter Pylori Eradication in Mexico With a Levofloxacin-containing Scheme Versus Clarithromycin-based Triple Therapy: a Randomized, Open-label, Non-inferiority, Phase 3b Trial.

Sponsor: Asofarma de México S.A de C.V.

Conditions Helicobacter Pylori Gastritis

Interventions CLA (Clarithro+Lanso+Amoxi) PLA (Panto+Levoflox+Azithro)

Updated 5 times since 2017 Last updated: Mar 31, 2016 Started: Jun 30, 2012 Primary completion: Mar 31, 2014 Completion: May 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Helicobacter Pylori Gastritis, this trial is completed. The trial is conducted by Asofarma de México S.A de C.V. and has accumulated 5 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jun 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Asofarma de México S.A de C.V.
Centro InmunoQ, Mexico City
Centro Médico ABC Observatorio, Mexico City
Hospital Ángeles Metropolitano, Mexico City
Hospital Ángeles, Clínica Londres, Mexico City
Torre Mayo, Metepec, State of Mexico

Data source: Asofarma de México S.A de C.V.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.